Connect Biopharma announces positive preliminary Phase 2 topline data for rademikibart add-on in COPD

Connect Biopharma said its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation produced positive preliminary topline data.